<DOC>
	<DOCNO>NCT02610231</DOCNO>
	<brief_summary>This Phase 3 , 52-week , open-label , flexible-dose , multinational , multicenter study evaluate safety tolerability istradefylline 20 40 mg/d subject moderate severe PD motor fluctuation dyskinesia levodopa combination ( levodopa/carbidopa levodopa/benserazide ) therapy plus least one adjunctive PD medication . Subjects complete 12 week double-blind treatment 30-day follow-up period Study No . 6002-014 undergo Screening Baseline evaluation eligibility study . Eligible subject treat istradefylline start dose 20 mg/d option dose adjustment 40 mg/d Week 12 base Investigator 's judgment subject 's response tolerability . If deem necessary , one unscheduled dose adjustment visit Week 2 Week 12 allow accordance clinical judgment Investigator . Subjects dose adjustment 40 mg/d dose decrease 20 mg/d Investigator second unscheduled dose adjustment visit tolerability issue . The istradefylline dose remain fixed Week 26 Week 52 . Consultation Sponsor 's Medical Monitor require prior unscheduled dose adjustment visit . A subject may discontinue study time .</brief_summary>
	<brief_title>Long Term Study Istradefylline Subjects With Moderate Severe Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Istradefylline</mesh_term>
	<criteria>1 . Written informed consent ; 2 . Subjects complete Study No . 6002014 inclusive 30day followup period ; 3 . Currently take levodopa combination ( carbidopa/levodopa benserazide/levodopa ) therapy plus least one adjunctive PD medication ; 4 . Women childbearing potential ( WOCBP ) must use reliable method contraception negative serum pregnancy test Screening ; 1 . Subjects less 70 % treatment compliance throughout enrollment Study No 6002014 major protocol deviation Study No . 6002014 ( subject fail meet inclusion criterion , subject meet exclusion criterion subject meet criterion subject withdrawal withdrawn ) ; 2 . Subjects apomorphine and/or dopamine receptor antagonist direct gastrointestinal levodopa infusion ; 3 . Subject neurosurgical operation PD ; 4 . Subjects take A2a antagonist , potent CYP3A4 inhibitor , potent CYP34A inducer ; 5 . Subjects diagnosis cancer evidence continue malignancy within past three year ( exception adequately treat basal cell squamous cell skin cancer , situ cervical cancer , situ prostate cancer normal prostatespecific antigens post resection ) .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Moderate Severe Parkinson 's Disease</keyword>
</DOC>